The objective of this study is to assess whether statin use is associated with beneficial effects on @entity1030 outcomes. We conducted a systematic review and meta-analysis of all available studies describing the association between statin use and @entity1030 mortality, exacerbations and cardiovascular events. Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were searched, with no restrictions. The hazard ratio (HR) with 95% confidence interval (CI) was estimated. Fifteen studies with a total of 238,459 @entity1 were included. Nine articles provided data on all-cause mortality (124,543 @entity1 ), and they gave a HR of 0.62 (95% CI 0.52 to 0.73). Three studies provided data on @entity5 mortality (90,077 @entity1 ), HR 0.83 (0.65 to 1.08); four studies on @entity1030 mortality (88,767 @entity1 ), HR 0.48 (0.23 to 0.99); and three studies on cardiovascular mortality (90,041 @entity1 ), HR 0.93 (0.50 to 1.72). Six articles provided data on @entity1030 exacerbation with or without hospitalization (129,796 @entity1 ), HR 0.64 (0.55 to 0.75). Additionally, the use of statins was associated with a significant reduction risk of @entity583 , but not for @entity64 . Our systematic review showed a clear benefit of statins in @entity1 with @entity1030 .

The effect of statins on XXXX exacerbation and mortality: a systematic review and meta-analysis of observational research.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['COPD'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']
@entity1030 :: (MESH:D029424,Disease) :: ['chronic obstructive pulmonary disease']
